Structured evidence table for Pomegranate Supplementation Blood Pressure Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Pomegranate Supplementation Blood Pressure Meta-Analysis | However, current clinical evidence remains inconclusive, with meta-analyses revealing heterogeneity in intervention outcomes across randomized controlled trials. | 1 | Wu D (2025) | Efficacy and safety of dietary polyphenol supplements for COPD: a systematic review and meta-analysis. |
| Pomegranate Supplementation Blood Pressure Meta-Analysis | These results provide graded evidence for personalized nutritional interventions, promoting the transformation of polyphenol preparations from dietary supplements to precision adjuvant therapies. | 1 | Wu D (2025) | Efficacy and safety of dietary polyphenol supplements for COPD: a systematic review and meta-analysis. |
| Pomegranate Supplementation Blood Pressure Meta-Analysis | Background The therapeutic application of dietary polyphenols in chronic obstructive pulmonary disease (COPD) management represents an emerging therapeutic paradigm in pulmonary medicine. | 1 | Wu D (2025) | Efficacy and safety of dietary polyphenol supplements for COPD: a systematic review and meta-analysis. |
| Pomegranate Supplementation Blood Pressure Meta-Analysis | Thus, the aim of our study is to evaluate the effects of pomegranate peel extract (PP) supplementation on hepatic status and metabolic syndrome risk factors. | 2 | Barghchi H (2023) | Pomegranate (Punica granatum L.) peel extract ameliorates metabolic syndrome risk factors in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial. |
| Pomegranate Supplementation Blood Pressure Meta-Analysis | Introduction Non-alcoholic fatty liver disease (NAFLD) is a metabolic syndrome (MS)-related liver disorder that has an increasing prevalence. | 2 | Barghchi H (2023) | Pomegranate (Punica granatum L.) peel extract ameliorates metabolic syndrome risk factors in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial. |
Source documents